Clinical trials: Immediate Hypersensitivity
Urticaria
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
This study is being done to find out if a drug called Abatacept (Orencia ®) is safe and effective in treating people with chronic urticaria (persistent hives).
- Trial name
- TAHOE (NCT00886795)
- Testing
- abatacept (Orencia ®)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Johns Hopkins University
Eosinophilic Esophagitis
Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis
This study is being done to see if allergy patch testing (APT) can help predict effective dietary therapy in patients with eosinophilic esophagitis.
- Trial name
- EoE (NCT02227836)
- Testing
- Allergy Patch Testing
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Peanut Allergy
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17…
- Trial name
- NCT03703791
- Testing
- AR101
- Where
- 11 sites in Spain
- Volunteers
- 1 people
- Sponsor
- Aimmune Therapeutics, Inc.
Asthma
Pharmacogenetics of b2-Agonists in Asthma.
This study will help to find out if having a certain genetic makeup influences how a person with asthma responds to salmeterol, one of the two drugs in Advair(R).
- Trial name
- NCT00708227
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Nemours Children's Clinic
Allergic Conjunctivitis
A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Safety and efficacy of DE-114 ophthalmic solution will be evaluated in patients with allergic conjunctivitis, in an open-label, multicenter study.
- Trial name
- NCT01363713
- Testing
- DE-114 ophthalmic solution
- Where
- Japan
- Volunteers
- 130 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Asthma
Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on medium doses of ICS-LABA.
- Trial name
- NCT01947946
- Testing
- Benralizumab
- Where
- 47 sites in United States, Argentina and 5 more
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Chronic Idiopathic Urticaria
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment…
- Trial name
- NCT01287117
- Testing
- Omalizumab
- Where
- 66 sites in United States, Denmark and 6 more
- Volunteers
- 319 people
- Sponsor
- Genentech, Inc.
Atopic Dermatitis
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Heads Up (NCT03738397)
- Testing
- Upadacitinib, Dupilumab
- Where
- 159 sites in United States, Australia and 21 more
- Volunteers
- 673 people
- Sponsor
- AbbVie
Asthma
Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Primary objective To show the superiority of CHF 1535 (BDP/FF) pMDI (800/24 μg per day) over BDP HFA pMDI (800 μg per day) in terms of change from baseline to the entire treatment period in average pre-dose morning peak…
- Trial name
- FORCE (NCT01577082)
- Testing
- CHF1535 200/6 µg pMDI, BDP HFA 100 µg pMDI
- Where
- 66 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 542 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial
Asthma is an inflammatory disease that imposes a significant burden affecting an estimated 300 million persons and 20% of all children worldwide.
- Trial name
- MICT (NCT02061280)
- Testing
- fluticasone/salmeterol 250/50 Dry Powder Inhaler, fluticasone/salmeterol 100/50 Dry Powder Inhaler, fluticasone 100mcg Dry Powder Inhaler
- Where
- 5 sites in United States
- Volunteers
- 108 people
- Sponsor
- Nemours Children's Clinic
Asthma
Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler
This study aims to explore the potential impact of switching inhalers by assessing the handling error rate (critical and non-critical) in controlled asthmatics currently treated with, and using correctly, SERETIDE via the DISKUS…
- Trial name
- NCT02416180
- Testing
- SERETIDE MDI
- Where
- 7 sites in Germany
- Volunteers
- 111 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060
The primary objective of this study was to evaluate microbial density in eczematous lesions during two weeks of twice daily therapy with the investigational product, DPK-060 1% ointment, compared with placebo in patients with…
- Trial name
- NCT01522391
- Testing
- DPK-060 1% ointment
- Where
- Sweden
- Volunteers
- 41 people
- Sponsor
- DermaGen AB
Asthma, Allergy
Dietary Interventions in Asthma Treatment: Sprouts Study
Sulforaphane (SFN) is a naturally occurring isothiocyanate that is a potent inducer of Phase II enzymes which play a critical role in preventing oxidative stress (via activation of Nrf2).
- Trial name
- NCT01183923
- Testing
- Broccoli Sprouts, Alfalfa Sprouts
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Asthma
Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)
Hypotheses: 1) Airway pH regulation is abnormal in severe asthma; 2) In severe asthma, there is formation of cytotoxic nitrogen oxides and loss of beneficial nitrogen oxides in the airways
- Trial name
- SARP (NCT00590005)
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Emory University
Asthma
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through…
- Trial name
- NCT06702462
- Testing
- HFA-152A propellant, HFA-134A propellant
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for up to 26 doses.
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
- Trial name
- NCT03664960
- Testing
- AK002
- Where
- 17 sites in United States
- Volunteers
- 58 people
- Sponsor
- Allakos Inc.
Asthma, COPD
Leukocyte Function in Asthma and COPD
The aim of this study is to examine the inflammatory mechanisms involved in the pathogenesis of inflammatory lung disease, in particular to compare the inflammatory profile seen in asthma and COPD.
- Conditions
- Asthma, COPD, Emphysema, Chronic Bronchitis
- Trial name
- NCT00147069
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Asthma
Internet Telehealth for Pediatric Asthma Case Management
The original and primary aim of this study is to evaluate the effects of CHESS with Nurse Case Management on asthma control (symptom-free days), and adherence factors of children aged 4-12.
- Trial name
- CHESS (NCT00214383)
- Testing
- CHESS Internet telehealth
- Volunteers
- 301 people
- Sponsor
- University of Wisconsin, Madison
Atopic Dermatitis
5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical…
- Trial name
- NCT00120523
- Testing
- Pimecrolimus, Topical corticosteroids
- Where
- 31 sites in United States, Germany
- Volunteers
- 2,418 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- BREEZE-AD6 (NCT03559270)
- Testing
- Baricitinib
- Where
- 74 sites in United States, Canada and 1 more
- Volunteers
- 374 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.